Emerging studies indicate that MIIP is downregulated in a variety of human tumors, including prostate cancer, glioma, lung cancer, colon cancer, endometrial carcinoma, and pancreatic cancer; moreover, its expression level is correlated with advanced clinical stage and patient prognosis20–23. Here, MIIP is linked to pancreatic neoplasm.